LD-2 disclosure · 2nd Quarter - Amendment

AMNEAL PHARMACEUTICALS

2nd Quarter (Apr 1 - June 30) · 2024Posted Nov 12, 2024Filing document ↗LDA record ↗

Expenses$170Kself-filed spend

Client

1 issue

Health Issues
Addressing drug shortages and enhancing domestic production of critical medicines Issues related to biosimilars Promoting long-term sustainability of access for patients to generic and biosimilar medicines Lower Costs, More Transparency Act (H.R. 5378) H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023 H.R.1352: Increasing Access to Biosimilars Act of 2023 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 Senate Finance Committee drug shortage legislation Appropriations pertaining to American Made preference for generic products Issues related to Medicaid Generics Penalty Issues related to DEA Quota Issues related to drug supply chain
LobbyistsJULIAN MALASI
TargetedSENATE · HOUSE OF REPRESENTATIVES

LD-2 disclosure · 2nd Quarter - Amendment

2nd Quarter (Apr 1 - June 30) · 2024Posted Nov 12, 2024Filing document ↗LDA record ↗

Expenses$170Kself-filed spend

1 issue

Health Issues
Addressing drug shortages and enhancing domestic production of critical medicines Issues related to biosimilars Promoting long-term sustainability of access for patients to generic and biosimilar medicines Lower Costs, More Transparency Act (H.R. 5378) H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023 H.R.1352: Increasing Access to Biosimilars Act of 2023 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 Senate Finance Committee drug shortage legislation Appropriations pertaining to American Made preference for generic products Issues related to Medicaid Generics Penalty Issues related to DEA Quota Issues related to drug supply chain
LobbyistsJULIAN MALASI
TargetedSENATE · HOUSE OF REPRESENTATIVES